X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PANACEA BIOTECH - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PANACEA BIOTECH IPCA LABS/
PANACEA BIOTECH
 
P/E (TTM) x 27.5 80.4 34.2% View Chart
P/BV x 2.1 1.8 117.9% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   PANACEA BIOTECH
EQUITY SHARE DATA
    IPCA LABS
Mar-17
PANACEA BIOTECH
Mar-14
IPCA LABS/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs643149 432.4%   
Low Rs50382 610.9%   
Sales per share (Unadj.) Rs254.484.1 302.4%  
Earnings per share (Unadj.) Rs16.1-18.3 -87.8%  
Cash flow per share (Unadj.) Rs29.8-6.7 -444.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.683.7 232.4%  
Shares outstanding (eoy) m126.2061.25 206.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.31.4 164.1%   
Avg P/E ratio x35.7-6.3 -565.1%  
P/CF ratio (eoy) x19.2-17.2 -111.6%  
Price / Book Value ratio x2.91.4 213.4%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3007,074 1,022.0%   
No. of employees `00013.32.8 483.7%   
Total wages/salary Rs m6,9601,449 480.3%   
Avg. sales/employee Rs Th2,413.51,874.1 128.8%   
Avg. wages/employee Rs Th523.2527.0 99.3%   
Avg. net profit/employee Rs Th152.4-407.7 -37.4%   
INCOME DATA
Net Sales Rs m32,1065,154 623.0%  
Other income Rs m226100 226.2%   
Total revenues Rs m32,3325,254 615.4%   
Gross profit Rs m4,448-766 -580.4%  
Depreciation Rs m1,730711 243.2%   
Interest Rs m2411,503 16.0%   
Profit before tax Rs m2,703-2,881 -93.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m67517 4,019.0%   
Profit after tax Rs m2,028-1,121 -180.9%  
Gross profit margin %13.9-14.9 -93.2%  
Effective tax rate %25.0-0.6 -4,282.7%   
Net profit margin %6.3-21.8 -29.0%  
BALANCE SHEET DATA
Current assets Rs m17,3403,810 455.1%   
Current liabilities Rs m9,5598,365 114.3%   
Net working cap to sales %24.2-88.4 -27.4%  
Current ratio x1.80.5 398.2%  
Inventory Days Days100156 64.4%  
Debtors Days Days5767 84.6%  
Net fixed assets Rs m20,77914,480 143.5%   
Share capital Rs m25261 411.7%   
"Free" reserves Rs m24,499903 2,712.7%   
Net worth Rs m24,5535,127 478.9%   
Long term debt Rs m3,5175,832 60.3%   
Total assets Rs m39,59519,433 203.7%  
Interest coverage x12.2-0.9 -1,334.0%   
Debt to equity ratio x0.11.1 12.6%  
Sales to assets ratio x0.80.3 305.8%   
Return on assets %5.72.0 291.7%  
Return on equity %8.3-21.9 -37.8%  
Return on capital %10.53.6 288.4%  
Exports to sales %48.624.5 198.4%   
Imports to sales %14.210.2 139.8%   
Exports (fob) Rs m15,6171,264 1,235.7%   
Imports (cif) Rs m4,571525 871.0%   
Fx inflow Rs m15,6171,539 1,014.6%   
Fx outflow Rs m5,828942 618.7%   
Net fx Rs m9,790597 1,639.3%   
CASH FLOW
From Operations Rs m2,764599 461.3%  
From Investments Rs m-1,432-438 326.9%  
From Financial Activity Rs m-1,591-303 525.9%  
Net Cashflow Rs m-259-141 183.2%  

Share Holding

Indian Promoters % 45.9 74.5 61.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.6 1,900.0%  
FIIs % 25.3 1.3 1,946.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 23.6 73.7%  
Shareholders   36,892 10,259 359.6%  
Pledged promoter(s) holding % 2.1 35.1 6.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  ALEMBIC LTD  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 22, 2017 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS